These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37529461)

  • 21. Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer.
    Zhang D; Kong F; Gao F; Li L; Liang Y; Yu M; Zhao L; Wang N; Jia Y
    Heliyon; 2024 Jan; 10(1):e22913. PubMed ID: 38148793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV/AIDS in China.
    Xiong Y; Mo P; Yan Y; Wang S; Zhuang K; Ma Z; Chen X; Deng L; Xiong Y; Deng D; Zhang Y
    Front Oncol; 2023; 13():1248790. PubMed ID: 37799470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients.
    Tian J; Sui L; Wang H; Chen X
    Front Oncol; 2023; 13():1180735. PubMed ID: 37469402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: An open-label, phase 2 trial.
    Zhang X; Chen J; Liu N; Wang Q; Wu Q; Gao F; Sang Y; Wang P
    J Cancer Res Ther; 2022 Apr; 18(2):482-487. PubMed ID: 35645118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactive cutaneous capillary endothelial proliferations of the eyelids induced by camrelizumab: A case report.
    Zhou X; Yan X; Wu Y
    Biomed Rep; 2024 Mar; 20(3):53. PubMed ID: 38357230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101).
    Wang R; Shi M; Ji M; Han Z; Chen L; Liu Y; Lu K; Liu L; Chen B; Zhang X; Miao L; Shu Y
    Transl Lung Cancer Res; 2023 Apr; 12(4):786-796. PubMed ID: 37197631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer.
    Xu M; Meng X; Lu Y; Wang F
    J Gastrointest Oncol; 2022 Apr; 13(2):548-558. PubMed ID: 35557572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.
    Chen Y; Zhang H; Shi J; Wang T
    Onco Targets Ther; 2020; 13():12471-12476. PubMed ID: 33299330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Camrelizumab: an investigational agent for hepatocellular carcinoma.
    Xu B; Sun HC
    Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study.
    Yan Z; Ma J; Yao S; Yao Z; Wang H; Chu J; Zhao S; Liu Y
    Front Immunol; 2021; 12():727464. PubMed ID: 34899689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma.
    Ju H; Wei D; Wu Y; Liu Y; Ding Q; Rui M; Fan Z; Yao Y; Hu J; Ren G
    MedComm (2020); 2023 Aug; 4(4):e312. PubMed ID: 37492783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case report: A case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: A new immune-related adverse event.
    Wu PS; Xiong D; Feng YB; Xiang L; Zhu J
    Front Immunol; 2022; 13():939873. PubMed ID: 36090986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.
    Xiang J; Gong W; Sun P; Wang X; Liu A
    J Gastrointest Oncol; 2022 Dec; 13(6):2874-2884. PubMed ID: 36636085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
    Ren Y; Liu Z; Makamure J; Kan X; Song S; Liu Y; Qian K; Zheng C; Liang B
    Technol Cancer Res Treat; 2022; 21():15330338221131385. PubMed ID: 36259117
    [No Abstract]   [Full Text] [Related]  

  • 36. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
    Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
    Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical application of camrelizumab on advanced hepatocellular carcinoma.
    Chen Z; Lu X; Koral K
    Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1017-1024. PubMed ID: 32762583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer.
    Li W; Wei Z; Yang X; Huang G; Han X; Ni Y; Wang J; Meng M; Zou Z; Wen Q; Ye X
    J Cancer Res Ther; 2019; 15(7):1624-1628. PubMed ID: 31939447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer.
    Wei Z; Yang X; Ye X; Huang G; Li W; Han X; Wang J; Meng M; Ni Y; Zou Z; Wen Q
    J Cancer Res Ther; 2019; 15(7):1629-1634. PubMed ID: 31939448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.
    Lickliter JD; Gan HK; Voskoboynik M; Arulananda S; Gao B; Nagrial A; Grimison P; Harrison M; Zou J; Zhang L; Luo S; Lahn M; Kallender H; Mannucci A; Somma C; Woods K; Behren A; Fernandez-Penas P; Millward M; Meniawy T
    Drug Des Devel Ther; 2020; 14():1177-1189. PubMed ID: 32256049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.